Boston Scientific's trading volume on March 6th was $718 million, ranking 178th among U.S. stocks on that day.

On March 6, 2026, medical device company Boston Scientific (BSX) had trading value of $718 million, ranking 178th among U.S. stocks that day. Trading value decreased by 22.24% from the previous day, and trading volume was 10.03M shares that day.

Boston Scientific (BSX) fell 2.25% on March 6, 2026, to $71.35. Over the past 5 trading days, the stock fell 7.16%. For the entire month of March, it fell 7.16%. Year-to-date, it is down 25.17%. Over the past 52 weeks, it has fallen 29.22%.

*If the company has been listed for less than 52 weeks, the 52-week gain/loss is calculated as the gain/loss from the listing date (the same applies to cases where the listing duration is less than 1 month or fewer than 5 trading days)

Boston Scientific International Ltd. traces its history back to the late 1960s. The company is a global developer, manufacturer, and seller of medical devices that are widely used in interventional medical specialties. The company’s endoscopy business develops and manufactures equipment used for diagnosing and treating invasive and minimally invasive techniques to diagnose and treat a wide range of gastrointestinal and lung diseases. The urology and pelvic health business develops and manufactures equipment used to treat various urological and pelvic diseases affecting both male and female anatomical structures, including kidney stones, benign prostatic hyperplasia (BPH), prostate cancer, erectile dysfunction, incontinence, pelvic floor disorders, abnormal uterine bleeding, uterine fibroids, and polyps. The company’s cardiac rhythm management (CRM) business develops and manufactures various implantable devices that can monitor the heart and deliver electrical therapy to treat cardiac abnormalities. The company’s electrophysiology business develops and manufactures minimally invasive medical technologies used to diagnose and treat disturbances in the heart’s rate and rhythm, including a broad range of interventional and diagnostic catheter products and various devices used in electrophysiology laboratories. The company’s Neuromodulation business develops and manufactures equipment used to treat various neurological movement disorders and manage chronic pain. The company’s interventional cardiology business develops, manufactures, and commercializes technologies used to diagnose and treat coronary artery disease and other cardiovascular diseases (including structural heart disease).